Doxazosin Tablet
Product Images NDC 71610-831

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 71610-831). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0831 53)

Label for Doxazosin USP 8 mg oral tablets, package of 60 tablets. Manufactured by Zydus Lifesciences Ltd., Ahmedabad, India, and packaged by Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. Includes storage instructions, barcode, NDC number 71610-831-53, batch number, and expiration date fields.*

FDA Label Image

Doxazosin Tablets, Usp (92ead971 9de8 4240 B2c7 Fc2e9abac7dd 01)

Chemical structure of doxazosin, depicted with its characteristic heterocyclic rings, methoxy substituents, and sulfonic acid group, representing the active ingredient in the prescription drug Doxazosin tablets 8 mg by Aphena Pharma Solutions.*

FDA Label Image

Doxazosin Tablets (92ead971 9de8 4240 B2c7 Fc2e9abac7dd 02)

Data table summarizing results from three clinical studies on Doxazosin showing symptom score and maximum flow rate changes compared to placebo. It presents mean baseline values, mean change from baseline, sample sizes, and statistical significance for different dosages including 4 mg and 8 mg in treatment groups. A corresponding bar chart compares maximum flow rate and symptom score changes in Study 2 for placebo, 4 mg, and 8 mg doses.*

FDA Label Image

Doxazosin Tablets, Usp (92ead971 9de8 4240 B2c7 Fc2e9abac7dd 03)

Two line graphs depicting clinical data for Doxazosin versus placebo over a 14-week treatment period. The first graph shows mean change in total symptom score from baseline, with a greater decrease for Doxazosin. The second graph displays mean increase in maximum urinary flow rate (mL/sec) from baseline, with higher improvements for Doxazosin. Both graphs indicate statistical significance at various points.*

FDA Label Image

Aphena (Aphena)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.